Anti-PD-L1 antibody
The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.
1. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of bovine; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of bovine, wherein the light chain constant region of the bovine antibody has the amino acid sequence as shown in SEQ ID NO: 100 and the heavy chain constant region of the bovine antibody has the amino acid sequence as shown in SEQ ID NO: 102.
2. The antibody of claim 1 , wherein the light chain variable region and the heavy chain variable region are derived from rat.
3. The antibody of claim 2 , wherein the light chain variable region is the light chain variable region of a rat anti-bovine PD-L1 antibody and the heavy chain variable region is the heavy chain variable region of a rat anti-bovine PD-L1 antibody.
4. The antibody of claim 3 , wherein the light chain variable region has the amino acid sequence as shown in SEQ ID NO. 1 and the heavy chain variable region has the amino acid sequence as shown in SEQ ID NO: 2.
5. The antibody of claim 1 which has a four-chain structure comprising two light chains and two heavy chains.
6. A pharmaceutical composition comprising the antibody of claim 1 as an active ingredient.
7. The pharmaceutical composition of claim 6 for treatment of cancers and/or infections.
8. The pharmaceutical composition of claim 7 , wherein the cancers and/or infections are selected from the group consisting of neoplastic diseases, leukemia, Johne's disease, anaplasmosis, bacterial mastitis, mycotic mastitis, mycoplasma infections, tuberculosis, Theileria orientalis infection, cryptosporidiosis, coccidiosis, trypanosomiasis and leishmaniasis.
9. An artificial genetic DNA encoding the antibody of claim 1 .
10. A vector comprising the artificial genetic DNA of claim 9 .
11. A host cell transformed with the vector of claim 10 .
12. A method of preparing an antibody, comprising culturing the host cell of claim 11 and collecting an anti-PD-L1 antibody from the resultant culture.
13. A DNA encoding a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of bovine an animal other than rat, wherein the heavy chain constant region of the bovine antibody has the amino acid sequence as shown in SEQ ID NO: 102.